Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This medication combines recombinant human epidermal growth factor (rh-EGF) with silver sulfadiazine (SSD), primarily used for wound healing, particularly in cases of chronic wounds, diabetic foot ulcers, and burn injuries. The combination appears to have synergistic effects in promoting wound healing while preventing infection. According to the search results, this combination has shown effectiveness in treating various types of wounds, including extravasation injuries in neonates[1], chronic wounds in adults[2], and diabetic foot ulcers[6]. Clinical studies have demonstrated that wounds treated with this combination healed completely in an average of 34 days (range 12 to 92 days)[2]. ## Mechanism of Action The combination works through complementary mechanisms: - **Recombinant Human Epidermal Growth Factor (rh-EGF)**: Stimulates skin regeneration and promotes healing by releasing growth factors that accelerate tissue repair[6]. - **Silver Sulfadiazine (SSD)**: Provides broad-spectrum antimicrobial activity to prevent infection in wounds. It works by stopping bacteria from producing folic acid, a vitamin required for bacterial multiplication[6]. In some formulations, this combination may also include chlorhexidine gluconate, which acts as an antiseptic and disinfectant to effectively clean the ulcer surface and further prevent infection[6][7]. ## Clinical Applications This combination has been used successfully in: - Treatment of diabetic foot ulcers[4][6] - Management of chronic wounds that failed conventional therapies[2] - Treatment of extravasation injuries in neonatal intensive care units[1] - Burn wound treatment[5] ## Side Effects Common side effects may include: - Skin irritation - Rash - Pain[6] The combination of epidermal growth factor with silver sulfadiazine appears to be more effective than silver sulfadiazine alone in promoting wound healing, particularly for wounds that have not responded to conventional treatments[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on epidermal growth factor + silver sulfadiazine.